Ignite Creation Date:
2025-12-24 @ 2:06 PM
Ignite Modification Date:
2026-02-07 @ 3:06 AM
Study NCT ID:
NCT01145495
Status:
COMPLETED
Last Update Posted:
2023-06-27
First Post:
2010-06-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 3 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 3 Follicular Lymphoma | View |
Keywords: